A review of kallikrein inhibitor lanadelumab in hereditary angioedema

Gloria Hwang, Ansh Johri, Sally Ng, Timothy Craig

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

Hereditary angioedema with C1 esterase inhibitor deficiency is a rare disorder characterized by unpredictable swelling of the face, larynx and gastrointestinal tract. Kallikreins are serine proteases that cleave kininogens to produce bradykinin leading to inflammation. A new prophylactic drug is lanadelumab (DX-2930, SHP-643), a recombinant, fully human IgG1 monoclonal antibody kallikrein inhibitor. Pharmacokinetics show a half-life of 14 days with a dose-dependent effect. Completed trials for lanadelumab include two Phase III studies with updated efficacy in preventing angioedema in hereditary angioedema patients. Ongoing data show the safety of the targeted therapy along with less frequent administration requirements. Information on long-term safety is still needed, as well as, further studies on the correlation of subcutaneous administered dosing requirements and severity of side effects.

Original languageEnglish (US)
Pages (from-to)937-943
Number of pages7
JournalImmunotherapy
Volume11
Issue number11
DOIs
StatePublished - Jan 1 2019

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology
  • Oncology

Cite this